Peptide Receptor Radionuclide Therapy Outcomes in a North American Cohort With Metastatic Well-Differentiated Neuroendocrine Tumors

Nancy Sharma, Boris G. Naraev, Eric G. Engelman, Bridget B. Zimmerman, David L. Bushnell, Thomas M. OʼDorisio, Sue S. OʼDorisio, Yusuf Menda, Jan Müller-Brand, James R. Howe, Thorvardur R. Halfdanarson

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

OBJECTIVES: The objective of this study was to describe the outcomes of patients in the University of Iowa Neuroendocrine Tumor (NET) Database treated with peptide receptor radionuclide therapy (PRRT). METHODS: One hundred thirty-five patients from the University of Iowa NET Database who received PRRT were analyzed, their characteristics were described, and survival was calculated. RESULTS: The median age at diagnosis was 51 years, and 64% were men. The primary tumor was located in the small bowel (SBNET) in 37.8%, in the pancreas (PNET) in 26.0%, in the lung in 13.3%, in unknown primary in 9.6%, and in other sites in 13.3%. A radiographic response of any magnitude was observed in 65.8%, 11.1% had a mixed response, and 15.4% showed progression. The overall survival (OS) from the first PRRT was 40 months, and the median time to progression was 23.9 months. Higher pretreatment chromogranin A and pancreastatin levels predicted inferior OS. CONCLUSIONS: Peptide receptor radionuclide therapy resulted in a relatively long OS and time to progression in heavily pretreated North American patients with advanced NETs. Elevated pretreatment chromogranin A and pancreastatin predicted shorter OS after therapy. Peptide receptor radionuclide therapy is a valuable treatment option in patients with advanced NETs, especially SBNETS.

Original languageEnglish (US)
JournalPancreas
DOIs
StateAccepted/In press - Oct 18 2016

Fingerprint

Peptide Receptors
Neuroendocrine Tumors
Radioisotopes
Survival
Chromogranin A
Therapeutics
Databases
Primitive Neuroectodermal Tumors
Pancreas
Lung
Neoplasms

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Hepatology
  • Endocrinology

Cite this

Sharma, N., Naraev, B. G., Engelman, E. G., Zimmerman, B. B., Bushnell, D. L., OʼDorisio, T. M., ... Halfdanarson, T. R. (Accepted/In press). Peptide Receptor Radionuclide Therapy Outcomes in a North American Cohort With Metastatic Well-Differentiated Neuroendocrine Tumors. Pancreas. https://doi.org/10.1097/MPA.0000000000000734

Peptide Receptor Radionuclide Therapy Outcomes in a North American Cohort With Metastatic Well-Differentiated Neuroendocrine Tumors. / Sharma, Nancy; Naraev, Boris G.; Engelman, Eric G.; Zimmerman, Bridget B.; Bushnell, David L.; OʼDorisio, Thomas M.; OʼDorisio, Sue S.; Menda, Yusuf; Müller-Brand, Jan; Howe, James R.; Halfdanarson, Thorvardur R.

In: Pancreas, 18.10.2016.

Research output: Contribution to journalArticle

Sharma, N, Naraev, BG, Engelman, EG, Zimmerman, BB, Bushnell, DL, OʼDorisio, TM, OʼDorisio, SS, Menda, Y, Müller-Brand, J, Howe, JR & Halfdanarson, TR 2016, 'Peptide Receptor Radionuclide Therapy Outcomes in a North American Cohort With Metastatic Well-Differentiated Neuroendocrine Tumors', Pancreas. https://doi.org/10.1097/MPA.0000000000000734
Sharma, Nancy ; Naraev, Boris G. ; Engelman, Eric G. ; Zimmerman, Bridget B. ; Bushnell, David L. ; OʼDorisio, Thomas M. ; OʼDorisio, Sue S. ; Menda, Yusuf ; Müller-Brand, Jan ; Howe, James R. ; Halfdanarson, Thorvardur R. / Peptide Receptor Radionuclide Therapy Outcomes in a North American Cohort With Metastatic Well-Differentiated Neuroendocrine Tumors. In: Pancreas. 2016.
@article{488f4268c5af4aa1a85267c8ec30f15c,
title = "Peptide Receptor Radionuclide Therapy Outcomes in a North American Cohort With Metastatic Well-Differentiated Neuroendocrine Tumors",
abstract = "OBJECTIVES: The objective of this study was to describe the outcomes of patients in the University of Iowa Neuroendocrine Tumor (NET) Database treated with peptide receptor radionuclide therapy (PRRT). METHODS: One hundred thirty-five patients from the University of Iowa NET Database who received PRRT were analyzed, their characteristics were described, and survival was calculated. RESULTS: The median age at diagnosis was 51 years, and 64{\%} were men. The primary tumor was located in the small bowel (SBNET) in 37.8{\%}, in the pancreas (PNET) in 26.0{\%}, in the lung in 13.3{\%}, in unknown primary in 9.6{\%}, and in other sites in 13.3{\%}. A radiographic response of any magnitude was observed in 65.8{\%}, 11.1{\%} had a mixed response, and 15.4{\%} showed progression. The overall survival (OS) from the first PRRT was 40 months, and the median time to progression was 23.9 months. Higher pretreatment chromogranin A and pancreastatin levels predicted inferior OS. CONCLUSIONS: Peptide receptor radionuclide therapy resulted in a relatively long OS and time to progression in heavily pretreated North American patients with advanced NETs. Elevated pretreatment chromogranin A and pancreastatin predicted shorter OS after therapy. Peptide receptor radionuclide therapy is a valuable treatment option in patients with advanced NETs, especially SBNETS.",
author = "Nancy Sharma and Naraev, {Boris G.} and Engelman, {Eric G.} and Zimmerman, {Bridget B.} and Bushnell, {David L.} and OʼDorisio, {Thomas M.} and OʼDorisio, {Sue S.} and Yusuf Menda and Jan M{\"u}ller-Brand and Howe, {James R.} and Halfdanarson, {Thorvardur R.}",
year = "2016",
month = "10",
day = "18",
doi = "10.1097/MPA.0000000000000734",
language = "English (US)",
journal = "Pancreas",
issn = "0885-3177",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Peptide Receptor Radionuclide Therapy Outcomes in a North American Cohort With Metastatic Well-Differentiated Neuroendocrine Tumors

AU - Sharma, Nancy

AU - Naraev, Boris G.

AU - Engelman, Eric G.

AU - Zimmerman, Bridget B.

AU - Bushnell, David L.

AU - OʼDorisio, Thomas M.

AU - OʼDorisio, Sue S.

AU - Menda, Yusuf

AU - Müller-Brand, Jan

AU - Howe, James R.

AU - Halfdanarson, Thorvardur R.

PY - 2016/10/18

Y1 - 2016/10/18

N2 - OBJECTIVES: The objective of this study was to describe the outcomes of patients in the University of Iowa Neuroendocrine Tumor (NET) Database treated with peptide receptor radionuclide therapy (PRRT). METHODS: One hundred thirty-five patients from the University of Iowa NET Database who received PRRT were analyzed, their characteristics were described, and survival was calculated. RESULTS: The median age at diagnosis was 51 years, and 64% were men. The primary tumor was located in the small bowel (SBNET) in 37.8%, in the pancreas (PNET) in 26.0%, in the lung in 13.3%, in unknown primary in 9.6%, and in other sites in 13.3%. A radiographic response of any magnitude was observed in 65.8%, 11.1% had a mixed response, and 15.4% showed progression. The overall survival (OS) from the first PRRT was 40 months, and the median time to progression was 23.9 months. Higher pretreatment chromogranin A and pancreastatin levels predicted inferior OS. CONCLUSIONS: Peptide receptor radionuclide therapy resulted in a relatively long OS and time to progression in heavily pretreated North American patients with advanced NETs. Elevated pretreatment chromogranin A and pancreastatin predicted shorter OS after therapy. Peptide receptor radionuclide therapy is a valuable treatment option in patients with advanced NETs, especially SBNETS.

AB - OBJECTIVES: The objective of this study was to describe the outcomes of patients in the University of Iowa Neuroendocrine Tumor (NET) Database treated with peptide receptor radionuclide therapy (PRRT). METHODS: One hundred thirty-five patients from the University of Iowa NET Database who received PRRT were analyzed, their characteristics were described, and survival was calculated. RESULTS: The median age at diagnosis was 51 years, and 64% were men. The primary tumor was located in the small bowel (SBNET) in 37.8%, in the pancreas (PNET) in 26.0%, in the lung in 13.3%, in unknown primary in 9.6%, and in other sites in 13.3%. A radiographic response of any magnitude was observed in 65.8%, 11.1% had a mixed response, and 15.4% showed progression. The overall survival (OS) from the first PRRT was 40 months, and the median time to progression was 23.9 months. Higher pretreatment chromogranin A and pancreastatin levels predicted inferior OS. CONCLUSIONS: Peptide receptor radionuclide therapy resulted in a relatively long OS and time to progression in heavily pretreated North American patients with advanced NETs. Elevated pretreatment chromogranin A and pancreastatin predicted shorter OS after therapy. Peptide receptor radionuclide therapy is a valuable treatment option in patients with advanced NETs, especially SBNETS.

UR - http://www.scopus.com/inward/record.url?scp=84992128564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992128564&partnerID=8YFLogxK

U2 - 10.1097/MPA.0000000000000734

DO - 10.1097/MPA.0000000000000734

M3 - Article

JO - Pancreas

JF - Pancreas

SN - 0885-3177

ER -